对于这次出售，百时美施贵宝对第一财经记者表示，公司将在全球网络内持续协调资源配置，以支持不 断发展的业务需求。按计划出售SASS工厂股权，体现了公司对生产战略的贯彻执行，这一战略旨在通 过强有力的外部合作来平衡内部资源，从而深化区域战略布局，并确保药物能够长期且有保障地提供给 中国乃至全球患者。 百时美施贵宝并非近年来唯一一家在华优化资产布局的跨国药企。 2024年8月，另外一家跨国药企优时比宣布，向康桥资本与穆巴达拉投资公司以6.8亿美元（约合49.26亿 人民币）出售公司在中国的成熟产品业务（涉及神经系统和抗过敏），包括开浦兰、维派特、优普洛、 仙特明、优泽五大产品及位于珠海的生产基地。 这是中国改革开放后首家中美合资制药企业。 9月15日晚间，第一财经记者从百时美施贵宝求证到，该公司已签署协议，出售在中美上海施贵宝制药 有限公司（即"SASS工厂"）中持有的60%股权。 这起出售，之所以引人关注，在于中美上海施贵宝制药有限公司在中国医药发展史上有着特殊的地位， 它是中国改革开放后首家中美合资制药企业，最早成立于1982年。 本次出售之前，百时美施贵宝持有SASS工厂60%股权，上海医药集团有限公司以及国 ...

中证报中证网讯（王珞）8月27日晚，康恩贝（600572）发布2025年半年度业绩报告。报告期内公司实 现营业收入33.58亿元，归母净利润3.54亿元；经营性现金流净额达4亿元，同比增长31%；销售费用率 和资产负债率均实现同比下降，整体经营质量得到提升。 公司坚持"中药大健康"核心战略，持续优化"一体两翼"业务布局。上半年，全品类中药业务收入保持稳 定，中药材与中药饮片板块实现收入5.83亿元，同比增长4.6%；特色健康消费品业务收入3.21亿元，同 比增长超过10%，显示出良好的增长韧性。 大品牌产品表现稳健，实现销售收入20.06亿元，同比有所增长。其中"康恩贝"肠炎宁系列通过多元营 销及渠道协同，销售收入突破5亿元，同比增长超15%；健康食品业务整体增长超10%，其中蛋白粉系 列销售收入过亿元、同比增长近30%；"金康灵力""金前列康"等品种销售增速均超20%，新推出的"康恩 贝"益生菌冻干粉也快速放量，形成新的增长点。 研发方面，公司上半年获中药改良型新药清喉咽含片批件1项、仿制药批件5项，恩替卡韦片和乙酰半胱 氨酸溶液获美国FDA批准上市。新立项研发项目74项，并通过剂型改良和循证研究持续提升核 ...

Core Viewpoint - Renhe Pharmaceutical (000650) has received the registration certificate for Entecavir tablets in 2021, which is an oral antiviral drug used for the treatment of hepatitis B infection [1] Company Summary - The company specializes in Entecavir, which selectively inhibits the hepatitis B virus [1] - Entecavir is primarily used for treating adults with active viral replication and persistently elevated serum transaminases, or with histologically active lesions in chronic hepatitis B [1]

Core Viewpoint - The company has received a drug registration certificate for Entecavir tablets in 2021, which is used for the treatment of hepatitis B infection [2]. Company Products - Entecavir is an oral antiviral medication that selectively inhibits the hepatitis B virus, primarily used for treating adults with active viral replication and elevated serum transaminases, or active disease in liver histology [2].

Core Viewpoint - Recent BD (business development) activities in the biopharmaceutical sector have garnered significant market attention, with companies like Rongchang Biopharmaceutical and China National Pharmaceutical Group announcing strategic partnerships and licensing agreements [1][2]. Group 1: Company Developments - Rongchang Biopharmaceutical's product, Tai'axip, has attracted interest from multinational pharmaceutical companies during the ERA conference, indicating potential for international collaboration and technology licensing [1]. - China National Pharmaceutical Group has identified out-licensing as a key strategic goal, engaging in discussions with multiple multinational pharmaceutical companies regarding innovative assets with global commercialization potential [1][2]. - Rongchang Biopharmaceutical reported a 94.87% year-on-year increase in sales volume for Tai'axip, reaching 1.5244 million units, showcasing strong commercial potential [3]. Group 2: Market Performance - Following positive announcements, Rongchang Biopharmaceutical's stock rose by 20.1% to HKD 57.65 per share, while China National Pharmaceutical Group's stock increased by 19.29% to HKD 5.69 per share [1]. - However, both companies experienced a stock price correction shortly after, with Rongchang Biopharmaceutical's share price dropping by 9.08% and China National Pharmaceutical Group's by 4.92% [1]. Group 3: Industry Trends - The biopharmaceutical sector is witnessing a surge in BD transactions, with the scale of these transactions surpassing traditional financing methods, becoming essential for biotech companies amid tightening capital markets [2][3]. - The Chinese innovative drug market is increasingly gaining international recognition, with a significant rise in the number and value of BD transactions, indicating a shift in global market dynamics [9][10]. - The trend of BD transactions is expected to continue, with a focus on innovative assets and diverse therapeutic targets, driven by both internal corporate strategies and external market conditions [10][11].

Core Viewpoint - Sunshine Nuohua (688621.SH) plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds, marking a significant asset restructuring and related party transaction [2][3] Group 1: Transaction Details - The transaction involves a major asset restructuring and is classified as a related party transaction due to shared controlling shareholders and actual controllers [2] - Sunshine Nuohua's stock fell by 3.63% upon resumption of trading, with a market capitalization of 4.962 billion yuan [2] - The acquisition aims to enhance the company's profitability and risk resistance by extending its business into the CDMO (Contract Development and Manufacturing Organization) field, creating an integrated "CRO+CDMO" service platform [3] Group 2: Strategic Shift - The acquisition reflects a strategic shift for Sunshine Nuohua from being a service provider in drug research and development to becoming a research-driven pharmaceutical company [3][4] - The company has begun developing its own drug pipeline and is exploring new areas such as traditional Chinese medicine and pet pharmaceuticals [4] Group 3: Financial Performance - Sunshine Nuohua's revenue growth is projected at only 15.70% for 2024, the lowest in its history, with a decline in net profit for the first time [4] - In Q1 2025, the company reported an 8.49% decline in revenue to 231 million yuan and a 59.34% drop in net profit to 30 million yuan [4] - R&D expenses have increased significantly, with a 39.02% rise in 2024 and a 7.32% increase in Q1 2025 [4] Group 4: Acquisition Challenges - The previous acquisition attempt was withdrawn due to significant changes in market conditions, and Langyan Life's performance has deteriorated, with a projected revenue drop of approximately 24.65% in 2023 [6][8] - Langyan Life's revenue for 2023 is expected to be 465 million yuan, down from 617 million yuan in 2022, with net profit also declining [6][7] - The high valuation of Langyan Life during the previous acquisition attempt may not be sustainable given its current financial struggles [8][10]